跳至主要内容
临床试验/NCT06402877
NCT06402877已完成不适用

Assessment of Saliva Adseverin,1-Alpha Defensin and sRANKL (Soluble RANKL) Levels In Individuals With Different Periodontal Diseases

Izmir Katip Celebi University2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2024年6月26日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
60
试验地点
2
主要终点
The total amount of 1-Alpha Defensin in saliva

研究概览

简要总结

: The aim of this study is; detection of Adseverin,1-alpha Defensin,sRANKL(soluble RANKL) levels in saliva samples of periodontally healthy, gingivitis and periodontitis patients and the possible correlation between these values and clinical parameters of periodontal diseases. Materials and methods: Samples of saliva were obtained from 60 systemically healthy non-smoker individuals with periodontitis (P, n=20), gingivitis(G, n=20) and healthy periodontium (S, n=20). Full-mouth clinical periodontal measurements including probing depth (PD), clinical attachment level (CAL), bleeding on probing (BOP), gingival index (GI) and plaque index (PI) were also recorded. Enzyme-linked immunosorbent assay (ELISA) was used to determine Adseverin,1-alpha Defensin,sRANKL(soluble RANKL) levels in the biological samples.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Cross Sectional

入排标准

年龄范围
20 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Systemically healthy (The determination of healthy volunteers will be based on the statements of the patients in the anamnesis. No additional examinations will be made.) At least twenty permanent teeth in the mouth Non-smoker No medication for continuous use Those who have not used antibiotics, anti-inflammatory and systemic corticosteroid drugs in the last 6 months.
  • Not in pregnancy or lactation period. For the periodontitis group that has not received periodontal treatment in the last 6 months For the periodontitis group; According to the evaluation made in 6 regions of each tooth, individuals with 30% or more bleeding on probing area, at least 2 teeth not adjacent to each quarter jaw with a depth of 5 mm or more and 4 mm or more attachment loss, coronal 1/3 and more on radiography (horizontal and / or vertical) bone loss For the gingivitis group; According to the evaluation made in 6 regions of each tooth, individuals with 10% or more bleeding on probing area, having a probing depth of less than 4mm and no attachment loss For healthy group; According to the evaluation made in 6 regions of each tooth,individuals with less than 10% bleeding on probing area, having a probing depth less than 4mm and no loss of attachment were included in the study.

排除标准

  • Any oral or systemic disease Regularly using a systemic medication During pregnancy or lactation Received periodontal treatment within the last 6 months. Those who received antibiotic, anti-inflammatory or systemic corticosteroid medication in the last 6 months Smokers are not included in the study

研究组 & 干预措施

Gingivitis

Experimental

Full-mouth clinical periodontal measurements recorded and saliva obtained.

干预措施: Saliva obtaining (Diagnostic Test)

Healthy Periodontium

Experimental

Full-mouth clinical periodontal measurements recorded and saliva obtain

干预措施: Saliva obtaining (Diagnostic Test)

Periodontitis

Experimental

Full-mouth clinical periodontal measurements recorded and saliva obtained.

干预措施: Saliva obtaining (Diagnostic Test)

结局指标

主要结局

The total amount of 1-Alpha Defensin in saliva

时间窗: 24 hours after taking the clinical measurements at the first visit

The total amount of 1-Alpha Defensin in saliva

The total amount of Adseverin in saliva

时间窗: 24 hours after taking the clinical measurements at the first visit]

The total amount of Adseverin in saliva

The total amount of sRANKL in saliva

时间窗: 24 hours after taking the clinical measurements at the first visit

The total amount of soluble RANKL in saliva

次要结局

未报告次要终点

研究者

发起方
Izmir Katip Celebi University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Ayşe Efe

Research Assistant at Periodontology

Izmir Katip Celebi University

研究点 (2)

Loading locations...

相似试验

Evaluation of Salivary Adseverin, 1-Alpha Defensin... | 临床试验